The shorters are scaring the market the obesity wonder drugs...

The shorters are scaring the market the obesity wonder drugs will reduce the market size of sleep apnea patients.
They ignore the healthy increase in the revenue and sales data in the quarterly results and they are not giving any credibility to RMD's modelling and tracking many thousands of patients on GLP-1s and PAP showing a high adherence rate and no real change.
Michael Farrell said "....there's many thousands of patients on our GLP-1 plus PAP database. We also have 17,000 patients that we're tracking that have had gone through bariatric surgery and our own PAP therapy post surgery with 50-plus percent weight loss reductions in that cohort."

Even if you doubt the management presentations and explanation, the costs for GLP-1 is exorbitant and does not stack up.
It is about $1,000 a month and at $12,000 per year it is much cheaper to treat the patient with PAP. I read the insurers and employers in the US are refusing to cover GLP-1 medication due to the high cost.

And there is still the unknown long term side effects of the medication.
Given the high costs and side effects, there is a serious question how long patient will adhere to the medication?

Michael said "We published this epidemiology model this quarter, and we'll continue to update it and continue to provide data."
He said the wonder drugs will have a positive impact for RMD by bringing patients into the funnel.

DYOR